ABSTRACT
The dopamine reuptake inhibitor bupropion has clinically been proven to improve depression and treatment-resistant depression. We examined its influence on the duration of immobility during the forced swim test in adrenocorticotropic hormone (ACTH)-treated rats and further analyzed the possible role of dopamine receptors in this effect. Additionally, the mechanism by which bupropion acts in this model was explored specifically in relation to the site of action through the use of microinjections into the medial prefrontal cortex and nucleus accumbens. Bupropion significantly decreased the duration of immobility in normal and ACTH-treated rats. This effect was blocked by D2 and D3 receptor antagonists in normal rats. Furthermore, infusions of bupropion into the nucleus accumbens, but not medial prefrontal cortex, decreased the immobility of normal and ACTH-treated rats during the forced swim test. Bupropion treatment plus repeated ACTH treatment significantly increased the extracellular dopamine concentration. These findings suggest the antidepressant-like effect of bupropion to be related to levels of dopamine in the rat nucleus accumbens.
Subject(s)
Bupropion/pharmacology , Cosyntropin/administration & dosage , Dopamine Uptake Inhibitors/pharmacology , Dopamine/metabolism , Motor Activity/drug effects , Nucleus Accumbens/drug effects , Animals , Bupropion/administration & dosage , Chromatography, High Pressure Liquid , Depression/drug therapy , Dopamine Uptake Inhibitors/administration & dosage , Immobilization , Male , Microdialysis , Microinjections , Nucleus Accumbens/metabolism , Rats , Rats, Wistar , Receptors, Dopamine/metabolism , SwimmingABSTRACT
The dopamine D2/D3 receptor agonist pramipexole has clinically been proven to improve depression or treatment-resistant depression. However, the involvement of the dopamine receptor system on the effect of pramipexole on depression remains unclear. We examined the influence of pramipexole on the duration of immobility during the forced swim test in normal and adrenocorticotropic hormone (ACTH)-treated rats and further analyzed the possible role of dopamine receptors in this effect. Additionally, the mechanism by which pramipexole acts in this model was explored specifically in relation to the site of action through the use of microinjections into the intramedial prefrontal cortex and nucleus accumbens. Pramipexole (0.3-1 mg/kg) significantly decreased the duration of immobility in normal and ACTH-treated rats. This effect was blocked by L-741,626, a D2 receptor antagonist, and nafadotride, a D3 receptor antagonist, in normal rats. Furthermore, infusions of pramipexole into the intranucleus accumbens, but not the medial prefrontal cortex, decreased the immobility of normal and ACTH-treated rats during the forced swim test. Taken together, the results of these experiments suggested that pramipexole, administered into the intranucleus accumbens rather than the medial prefrontal cortex, exerted an antidepressant-like effect on ACTH-treated rats via the dopaminergic system. The immobility-decreasing effect of pramipexole may be mediated by dopamine D2 and D3 receptors.
Subject(s)
Antidepressive Agents/pharmacology , Benzothiazoles/pharmacology , Depression/drug therapy , Dopamine Agonists/pharmacology , Adrenocorticotropic Hormone/administration & dosage , Animals , Antidepressive Agents/administration & dosage , Benzothiazoles/administration & dosage , Disease Models, Animal , Dopamine Agonists/administration & dosage , Dose-Response Relationship, Drug , Male , Microinjections , Motor Activity/drug effects , Nucleus Accumbens/metabolism , Pramipexole , Prefrontal Cortex/metabolism , Rats , Rats, Wistar , Receptors, Dopamine D2/agonists , Receptors, Dopamine D3/agonists , SwimmingABSTRACT
In the present study, we investigated the effect of adrenocorticotropic hormone (ACTH) on the immobilization of rats in the forced swim test after the administration of selegiline, a selective and irreversible monoamine oxidase (MAO)-B inhibitor. Single and repeated administration of selegiline significantly decreased the duration of immobility in normal rats. When selegiline was administered for 15 days, we observed a significant decrease in immobility in rats treated with ACTH for 14 days. The immobility-decreasing effect of selegiline was blocked by nafadotride, a selective dopamine D(3)-receptor antagonist in normal and ACTH-treated rats. Selegiline may be useful in an animal model of depressive conditions resistant to tricyclic antidepressant treatment via the dopamine D(3) receptor.
Subject(s)
Antidepressive Agents/pharmacology , Behavior, Animal/drug effects , Cosyntropin/pharmacology , Monoamine Oxidase Inhibitors/pharmacology , Selegiline/pharmacology , Animals , Benzazepines/pharmacology , Dopamine Antagonists/pharmacology , Dose-Response Relationship, Drug , Haloperidol/pharmacology , Male , Models, Animal , Motor Activity/drug effects , Naphthalenes/pharmacology , Pyrrolidines/pharmacology , Rats , Rats, Wistar , Receptors, Dopamine D3/drug effects , Swimming , Time FactorsABSTRACT
We examined the effect of chronic administration of imipramine and bupropion, monoamine reuptake inhibitors, on the duration of immobility in the forced swim test and serotonin (5-HT)(2A) receptor function in the form of 5-HT(2A) receptor mRNA levels in rats chronically treated with adrenocorticotropic hormone (ACTH). The immobility-decreasing effect of bupropion without imipramine did not influence the chronic ACTH treatment. The effect on the expression of 5-HT(2A) receptor mRNA of chronic ACTH treatment was decreased by bupropion, but not imipramine. These results suggest that bupropion has the effect of reducing immobility time in the forced swim test in the tricyclic antidepressant-resistant depressive model induced by chronic ACTH treatment in rats, and that decreased 5-HT(2A) receptor mRNA levels may be involved in this phenomenon.
Subject(s)
Adrenocorticotropic Hormone/pharmacology , Antidepressive Agents, Second-Generation/pharmacology , Antidepressive Agents, Tricyclic/pharmacology , Bupropion/pharmacology , Imipramine/pharmacology , Motor Activity/drug effects , Receptor, Serotonin, 5-HT2A/biosynthesis , Swimming/psychology , Animals , Male , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain ReactionABSTRACT
The use of carbamazepine has been reported to be an effective treatment for severe depression. We have already shown that the antidepressant-like effects of tricyclic antidepressants in the rat forced swim test (FST) are blocked by chronic treatment with adrenocorticotropic hormone (ACTH). In the present study, we examined the effect of the chronic administration of carbamazepine on the FST and the wet-dog shakes induced by (+/-) -1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT(2A) receptor agonist, in ACTH-treated rats. Chronic administration of carbamazepine did not affect the duration of immobility in saline-treated and ACTH-treated rats. The reduction of immobility, induced by chronic administration of imipramine, was blocked by treatment with ACTH. When carbamazepine was administered concurrently with imipramine, we observed a significant decrease in immobility in rats treated with ACTH. Chronic ACTH treatment increased the number of the wet-dog shakes induced by DOI. This effect of ACTH was significantly increased by the coadministration of carbamazepine and imipramine. These results suggest that the use of carbamazepine together with tricyclic antidepressants had the effect of reducing immobility time in the FST in a tricyclic antidepressant-treatment-resistant depressive model induced by chronic ACTH treatment.
Subject(s)
Adrenocorticotropic Hormone/pharmacology , Antidepressive Agents/administration & dosage , Carbamazepine/administration & dosage , Depression/drug therapy , Imipramine/administration & dosage , Receptor, Serotonin, 5-HT2A/physiology , Amphetamines/pharmacology , Animals , Disease Models, Animal , Drug Therapy, Combination , Male , Rats , Rats, WistarABSTRACT
We examined the influence of imipramine, a traditional tricyclic antidepressant, on the binding to serotonin (5-HT)(2) receptors and levels of 5-HT(2A)-receptor mRNA in the frontal cortex of rats treated with adrenocorticotropic hormone (ACTH). Chronic treatment with ACTH significantly increased the binding of [(3)H]-ketanserin to 5-HT(2) receptors and the expression of 5-HT(2A)-receptor mRNA in the frontal cortex. However, it did not alter the concentration of 5-HT or 5-hydroxyindole acetic acid. The effect of chronic ACTH treatment on 5-HT(2) receptor and 5-HT(2A)-receptor mRNA levels was not altered by the chronic administration of imipramine. Also, imipramine did not affect the hyperfunction of 5-HT(2A) receptors caused by chronic ACTH treatment. These findings suggest that chronic treatment with ACTH acts to increase 5-HT(2A)-receptor synthesis through increased gene transcription, without modulating presynaptic serotonergic neurotransmission.
Subject(s)
Adrenocorticotropic Hormone/metabolism , Antidepressive Agents, Tricyclic/pharmacology , Cerebral Cortex/drug effects , Imipramine/pharmacology , Receptor, Serotonin, 5-HT2A/drug effects , Tremor/metabolism , Amphetamines , Animals , Binding Sites , Cerebral Cortex/metabolism , Disease Models, Animal , Hydroxyindoleacetic Acid/metabolism , Ketanserin/metabolism , Male , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT2A/genetics , Receptor, Serotonin, 5-HT2A/metabolism , Serotonin/metabolism , Serotonin Antagonists/metabolism , Serotonin Receptor Agonists , Time Factors , Tremor/chemically induced , Tremor/genetics , Tremor/prevention & control , Up-RegulationABSTRACT
We investigated the effect of imipramine on extracellular serotonin (5-HT) and noradrenaline concentrations in the medial prefrontal cortex of rats treated with adrenocorticotropic hormone (ACTH) for 14 days using in vivo microdialysis. Chronic ACTH treatment did not affect basal extracellular 5-HT and noradrenaline concentrations compared with chronic saline treatment. Acute imipramine treatment plus chronic ACTH treatment significantly increased extracellular 5-HT concentrations, compared with imipramine treatment alone. 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT), a 5-HT1A receptors full agonist, caused a significant decrease in extracellular 5-HT concentrations. However, its inhibitory effect was attenuated by the treatment with ACTH for 14 days. These findings suggest that chronic treatment with ACTH enhances the increasing effect release of 5-HT by imipramine through the desensitization of somatodendritic 5-HT1A autoreceptors.
Subject(s)
Adrenergic Uptake Inhibitors/pharmacology , Adrenocorticotropic Hormone/pharmacology , Antidepressive Agents, Tricyclic/pharmacology , Imipramine/pharmacology , Prefrontal Cortex/drug effects , Serotonin/metabolism , 8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Animals , Corticosterone/blood , Male , Norepinephrine/metabolism , Prefrontal Cortex/metabolism , Rats , Rats, Wistar , Serotonin 5-HT1 Receptor Agonists , Serotonin Receptor Agonists/pharmacologyABSTRACT
We examined the influence of 8-hydroxy-2-di-n-propylamino tetralin (8-OH-DPAT), a serotonin 1A (5-HT1A) receptor full agonist, on the wet-dog shake response induced by the (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI), a 5-HT2A receptor agonist, in adrenocorticotropic hormone (ACTH)-treated rats. Chronic ACTH (100 microg/rat, s.c.) treatment for 14 d increased the wet-dog shake response induced DOI. The 8-OH-DPAT inhibited the wet-dog shake response induced by DOI in rats with ACTH for 14 d. On the other hand, the 8-OH-DPAT-induced hypothermia and flat body posture were inhibited when ACTH was administered for 14 d. These findings suggest that chronic treatment with ACTH decreased the sensitivity of the 5-HT1A receptor system; however, the inhibitory effects from the 5-HT1A receptors to the 5-HT2A receptor system is not inhibited in ACTH-treated rats.
Subject(s)
8-Hydroxy-2-(di-n-propylamino)tetralin/pharmacology , Adrenocorticotropic Hormone/pharmacology , Amphetamines/pharmacology , Brain/drug effects , Receptors, Serotonin/drug effects , Serotonin Receptor Agonists/pharmacology , 8-Hydroxy-2-(di-n-propylamino)tetralin/adverse effects , Adrenocorticotropic Hormone/adverse effects , Amphetamines/adverse effects , Animals , Body Temperature/drug effects , Brain/metabolism , Dose-Response Relationship, Drug , Hypothermia/chemically induced , Hypothermia/metabolism , Hypothermia/prevention & control , Ketanserin/pharmacology , Male , Posture , Rats , Rats, Wistar , Receptor, Serotonin, 5-HT1A/drug effects , Receptor, Serotonin, 5-HT2A/drug effects , Receptors, Serotonin/metabolism , Serotonin Antagonists/pharmacology , Serotonin Receptor Agonists/adverse effects , Time Factors , Tremor/chemically induced , Tremor/metabolism , Tremor/prevention & controlABSTRACT
We examined the influence of imipramine, a serotonin (5-HT) and noradrenaline (NA) reuptake inhibitor, desipramine, a NA reuptake inhibitor, bupropion, a dopamine reuptake inhibitor, fluvoxamine, a selective 5-HT reuptake inhibitor, and mazindol, a catecholamine reuptake inhibitor, on a 5-HT2A receptor-mediated behavior, (+/-)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI)-induced wet-dog shakes, in naive and adrenocorticotropic hormone (ACTH)-treated rats. Chronic administration of imipramine, desipramine and mazindol suppressed the number of wet-dog shakes in naive rats. Chronic ACTH (100 microg/rat, s.c.) treatment increased the number. Chronic administration of imipramine did not decrease the number of wet-dog shakes in ACTH-treated rats. On the other hand, desipramine and mazindol inhibited the increase in wet-dog shakes in ACTH-treated rats. Fluvoxamine and bupropion did not have any effect on the (+/-)-DOI-induced response in naive and ACTH-treated rats. NA reuptake inhibitors may improve the hyperfunction of 5-HT2A receptors induced by chronic ACTH treatment.
